<DOC>
	<DOCNO>NCT02655471</DOCNO>
	<brief_summary>This pilot study intervention group patient tropical spastic paraparesis/ myelopathy evaluate virologic clinical response raltegravir plus zidovudine group patient .</brief_summary>
	<brief_title>Effect Raltegravir Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection</brief_title>
	<detailed_description>The study investigator develop The Tropical Medicine Institute Alexander von Humboldt referral center Peru diseases associate Human T-Lymphotropic Virus 1 Infection ( HTLV-1 ) . The Institute cohort around 600 patient currently follow around 20 25 new patient admit every year disease . This pilot study intervention group patient tropical spastic paraparesis/ myelopathy evaluate virologic clinical response raltegravir plus zidovudine group patient follow-up 48 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Paraparesis</mesh_term>
	<mesh_term>Paraparesis , Spastic</mesh_term>
	<mesh_term>Paraparesis , Tropical Spastic</mesh_term>
	<mesh_term>HTLV-I Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>human lymphotrophic virus 1 confirm Tropical Spastic Paraparesis recent onset ( less 4 year ) Pregnant breastfeed unwilling use contraception . Treatment immunosuppressive , immunomodulatory experimental treatment within last 6 month enrolment study . Patients present medical disorder poorly control diabetes arterial hypertension , severe cardiac insufficiency , unstable ischemic heart disease , abnormal liver function test ( &gt; 2.5 time upper limit normal ( ULN ) ) abnormal complete blood count ( particular leukopenia , define lymphocyte count &lt; 500 , neutrophil &lt; 1.5 platelet count &lt; 100 , thrombocytopenia &lt; 1.5 low limit normal ( LLN ) , medical condition , opinion chief investigator , would pose additional risk patient . Presence human immunodeficiency virus antibody . Patients active hepatitis B or/and C liver function test &gt; 2.5 time ULN Exposure investigational drug within 30 day enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>